The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
An Update of the Gleason Grading System
Abstract
PURPOSE: An update is provided of the Gleason grading system, which has evolved significantly since its initial description. MATERIALS AND METHODS: A search was performed using the MEDLINE(R) database and referenced lists of relevant studies to obtain articles concerning changes to the Gleason grading system. RESULTS: Since the introduction of the Gleason grading system more than 40 years ago many aspects of prostate cancer have changed, including prostate specific antigen testing, transrectal ultrasound guided prostate needle biopsy with greater sampling, immunohistochemistry for basal cells that changed the classification of prostate cancer and new prostate cancer variants. The system was updated at a 2005 consensus conference of international experts in urological pathology, under the auspices of the International Society of Urological Pathology. Gleason score 2-4 should rarely if ever be diagnosed on needle biopsy, certain patterns (ie poorly formed glands) originally considered Gleason pattern 3 are now considered Gleason pattern 4 and all cribriform cancer should be graded pattern 4. The grading of variants and subtypes of acinar adenocarcinoma of the prostate, including cancer with vacuoles, foamy gland carcinoma, ductal adenocarcinoma, pseudohyperplastic carcinoma and small cell carcinoma have also been modified. Other recent issues include reporting secondary patterns of lower and higher grades when present to a limited extent, and commenting on tertiary grade patterns which differ depending on whether the specimen is from needle biopsy or radical prostatectomy. Whereas there is little debate on the definition of tertiary pattern on needle biopsy, this issue is controversial in radical prostatectomy specimens. Although tertiary Gleason patterns are typically added to pathology reports, they are routinely omitted in practice since there is no simple way to incorporate them in predictive nomograms/tables, research studies and patient counseling. Thus, a modified radical prostatectomy Gleason scoring system was recently proposed to incorporate tertiary Gleason patterns in an intuitive fashion. For needle biopsy with different cores showing different grades, the current recommendation is to report the grades of each core separately, whereby the highest grade tumor is selected as the grade of the entire case to determine treatment, regardless of the percent involvement. After the 2005 consensus conference several studies confirmed the superiority of the modified Gleason system as well as its impact on urological practice. CONCLUSIONS: It is remarkable that nearly 40 years after its inception the Gleason grading system remains one of the most powerful prognostic factors for prostate cancer. This system has remained timely because of gradual adaptations by urological pathologists to accommodate the changing practice of medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epstein, J. I., Allsbrook, W. C., Amin, M. B., & Egevad, L. L. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000173646.99337.b1 · Cited by 2,763
Self-citationGleason, D. F., Mellinger, G. T., & The Veterans Administration Cooperative Urological Research Group Members of this group areS0022534717598894-57c401330b4195dbd1713587ed540477 Lino J. Arduino Veterans Administration Center (VAC), D. M. (1974) · Journal of Urology · doi:10.1016/s0022-5347(17)59889-4 · Cited by 2,214
Helpap, B., & Egevad, L. (2006) · Virchows Archiv · doi:10.1007/s00428-006-0310-6 · Cited by 160
The Will Rogers Phenomenon in Urological Oncology
Gofrit, O. N., Zorn, K. C., Steinberg, G. D., Zagaja, G. P., & Shalhav, A. L. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.08.125 · Cited by 119
Hattab, E. M., Koch, M. O., Eble, J. N., Lin, H., & Liang Cheng, C. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00998-5 · Cited by 102
Grading of Invasive Cribriform Carcinoma on Prostate Needle Biopsy
Latour, M., Amin, M. B., Billis, A., Egevad, L., Grignon, D. J., Humphrey, P. A., Reuter, V. E., Sakr, W., Srigley, J. R., Wheeler, T. M., et al. (2008) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318169e8fd · Cited by 94
Self-citationPoulos, C. K., Daggy, J., & Cheng, L. (2004) · Modern Pathology · doi:10.1038/modpathol.3800302 · Cited by 69
Patel, A. A., Chen, M., Renshaw, A. A., & D'Amico, A. V. (2007) · JAMA · doi:10.1001/jama.298.13.1533 · Cited by 65
Cited by
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., Van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,090
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
Bulten, W., Pinckaers, H., van Boven, H., Vink, R., de Bel, T., van Ginneken, B., van der Laak, J., Hulsbergen-van de Kaa, C., & Litjens, G. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30739-9 · Cited by 705
Drost, F.-J. H., Osses, D. F., Nieboer, D., Steyerberg, E. W., Bangma, C. H., Roobol, M. J., & Schoots, I. G. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012663.pub2 · Cited by 640
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Metadata
- Authors
- Epstein, J. I.
- Venue
- Journal of Urology
- Published
- 2010-02
- Volume
- 183
- Issue
- 2
- Pages
- 433-440
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1998118468
- Cited by
- 533
- References
- 8
- FWCI
- 21.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An Update of the Gleason Grading System. https://app.cochat.ai/papers/10.1016/j.juro.2009.10.046
- The paper
- Epstein, J. I. (2010). An Update of the Gleason Grading System. Journal of Urology. https://doi.org/10.1016/j.juro.2009.10.046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.